COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00058084
Recruitment Status : Completed
First Posted : April 9, 2003
Last Update Posted : February 23, 2017
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This randomized phase II trial is studying ixabepilone to see how well it works compared to mitoxantrone and prednisone in treating patients with metastatic prostate cancer that has not responded to paclitaxel, docetaxel, or hormone therapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Ixabepilone may reduce resistance to the drugs and allow the tumor cells to be killed. It is not yet known which chemotherapy regimen is more effective in treating metastatic prostate cancer

Condition or disease Intervention/treatment Phase
Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage IV Prostate Cancer Drug: ixabepilone Drug: mitoxantrone hydrochloride Drug: prednisone Phase 2

Detailed Description:


I. Determine the efficacy of ixabepilone (BMS-247550) vs mitoxantrone and prednisone, in terms of decline in prostate-specific antigen (PSA) levels, in patients with taxane-resistant, hormone-refractory metastatic prostate cancer.


I. Determine the safety of these regimens in these patients. II. Determine the objective response rate in patients with measurable disease who are treated with these regimens.

III. Determine the clinical activity of each of these regimens after crossover in patients who experience disease progression on their originally assigned treatment arm and switch to the other treatment arm.

OUTLINE: This is a randomized, crossover, multicenter study. Patients are stratified according to ECOG performance status (0 vs 1 or 2). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.

ARM II: Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21.In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients who progress while on treatment after at least 2 courses or discontinue treatment for any other reason may cross over to the other arm and receive treatment as above, beginning within 12 weeks of last study treatment on original arm.

Patients are followed every 3 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study Of BMS 247550 Or Mitoxantrone And Prednisone In Patients With Taxane Resistant Hormone Refractory Prostate Cancer
Study Start Date : March 2003
Actual Primary Completion Date : October 1, 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm I
Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.
Drug: ixabepilone
Given IV
Other Names:
  • BMS-247550
  • epothilone B lactam
  • Ixempra

Experimental: Arm II
Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: mitoxantrone hydrochloride
Given IV
Other Names:
  • CL 232315
  • DHAD
  • DHAQ
  • Novantrone

Drug: prednisone
Given orally
Other Names:
  • DeCortin
  • Deltra

Primary Outcome Measures :
  1. Response to the randomized treatment as determined by > 50% PSA response as measured by RECIST criteria [ Time Frame: Up to 3 months ]
    The frequency of response with 95% confidence limits for a binomial outcome will be calculated.

Secondary Outcome Measures :
  1. Frequency of any toxicity by grade [ Time Frame: Up to 3 months ]
  2. Response duration [ Time Frame: From the date PR or CR is first determined until the first evidence of progressive disease, assessed up to 3 months ]
    Will be estimated using the Kaplan-Meier product limit method.

  3. Time to progressive disease [ Time Frame: From the date protocol therapy is started until the first evidence of progressive disease, assessed up to 3 months ]
    Will be estimated using the Kaplan-Meier product limit method.

  4. Frequency of response to third-line (crossover) therapy [ Time Frame: Up to 3 months ]
    Estimates of response to third line treatment along with 95% confidence intervals will be calculated.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate
  • Metastatic disease (positive bone scan or measurable disease)
  • Progressive hormone-refractory disease

    • Based on 1 of the following:

      • Transaxial imaging
      • Rise in prostate-specific antigen (PSA)
      • Radionuclide bone scan
    • Must have undergone primary hormonal treatment (e.g., orchiectomy or gonadotropin-releasing hormone analog with or without an antiandrogen) and demonstrated disease progression after antiandrogen discontinuation as defined below:

      • Two consecutive rising PSA values, obtained at least 2 weeks apart, or documented osseous or soft tissue progression
      • For patients receiving flutamide, at least 1 PSA value must be obtained at least 4 weeks after flutamide discontinuation
      • For patients receiving bicalutamide or nilutamide, at least 1 PSA value must be obtained at least 6 weeks after antiandrogen discontinuation
    • Ineligible if sole manifestation of progression is an increase in disease-related symptoms
  • Meets 1 of the following criteria:

    • Measurable disease and an elevated PSA
    • Nonmeasurable disease and an elevated PSA, as follows:

      • Positive bone scan
      • PSA level at least 5 ng/mL, with increases on at least 2 successive occasions at least 2 weeks apart
    • New metastatic lesions by radionuclide bone scan
  • Must have received at least 2 courses of paclitaxel- or docetaxel-based therapy, with disease progression documented during therapy or no more than 60 days after cessation of therapy*
  • Testosterone < 50 ng/dL
  • No known active brain metastases
  • Performance status - ECOG 0-2
  • At least 12 weeks
  • Granulocyte count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Bilirubin < 1.5 times upper limit of normal (ULN)
  • AST and ALT < 3 times ULN
  • Creatinine ≤ 1.5 times ULN
  • Creatinine clearance > 40 mL/min
  • Ejection fraction ≥ lower limit of normal by MUGA or echocardiogram
  • No myocardial infarction within the past 6 months
  • No significant cardiovascular disease
  • No New York Heart Association class III or IV congestive heart failure
  • No active angina pectoris
  • Fertile patients must use effective contraception before, during, and for 3 months after study therapy
  • No prior hypersensitivity reaction to agents containing Cremophor®EL
  • No serious infection
  • No nonmalignant medical illnesses that are uncontrolled or whose control would be jeopardized by complications of study therapy
  • No psychiatric illness or social situation that would preclude study compliance
  • No motor or sensory neuropathy grade 2 or greater
  • No "currently active" second malignancy except nonmelanoma skin cancer

    • Patients are not considered to have a "currently active" malignancy provided they have completed therapy and are considered to have less than a 30% risk of relapse
  • No concurrent prophylactic colony-stimulating factors for myelosuppression
  • See Disease Characteristics
  • No more than 1 prior chemotherapy regimen
  • No prior mitoxantrone or epothilone
  • No other concurrent chemotherapy
  • See Disease Characteristics
  • At least 4 weeks since prior antiandrogens (e.g., flutamide) (6 weeks for bicalutamide or nilutamide)

    • Patients must continue primary androgen deprivation therapy with luteinizing hormone-releasing hormone agonist during study if prior orchiectomy was not performed
  • At least 4 weeks since prior systemic (including oral) corticosteroids except corticosteroids as part of first-line chemotherapy tapered off over 10-14 days prior to study entry
  • At least 4 weeks since any prior hormonal therapy, including megestrol or finasteride
  • No other concurrent systemic steroids
  • At least 4 weeks since prior radiotherapy
  • More than 8 weeks since prior radiopharmaceuticals (e.g., strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium)
  • No concurrent radiotherapy
  • See Disease Characteristics
  • At least 4 weeks since prior herbal products known to decrease PSA levels (e.g., Saw Palmetto or PC-SPES)
  • More than 4 weeks since other prior antiprostate cancer therapy
  • More than 4 weeks since prior systemic therapies for prostate cancer
  • No other concurrent investigational agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00058084

Layout table for location information
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94143-0875
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Jonathan Rosenberg University of California, San Francisco
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00058084    
Other Study ID Numbers: NCI-2012-02526
N01CM62206 ( U.S. NIH Grant/Contract )
CDR0000285731 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: April 9, 2003    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Epothilone B
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Sensory System Agents
Peripheral Nervous System Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Tubulin Modulators